EN | UA
EN | UA

Help Support

Back

Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with post herpetic neuralgia treated with extended-release gabapentin

Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with post herpetic neuralgia treated with extended-release gabapentin Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with post herpetic neuralgia treated with extended-release gabapentin
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with post herpetic neuralgia treated with extended-release gabapentin Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with post herpetic neuralgia treated with extended-release gabapentin

Post herpetic neuralgia (PHN) interferes with patients’ quality of life, and disturbed sleep is a prevalent complaint. 

See All

Key take away

The sleep patterns are greatly affected in post herpetic neuralgia patients causing inadequate or poor quality sleep. In normal adults and epileptic patients, gabapentin is thought to improve sleep quality by increasing slow-wave sleep. Thus, findings of this study depict that a direct effect on sleep may have contributed to improvements in BPISI independent of pain reduction.

Background

Post herpetic neuralgia (PHN) interferes with patients’ quality of life, and disturbed sleep is a prevalent complaint. Pain-associated sleep interference in turn enhances pain and/or reduces pain tolerance. Therefore, reducing sleep interference by pain, in addition to pain control, may improve patient care. To address this notion, we characterized relationships among changes in pain intensity, sleep interference, and overall impression of improvement in PHN patients treated with gastro retentive gabapentin (G-GR).

Method

Patients with PHN (n = 556) received G-GR 1800 mg once-daily in two phase 3 and one phase 4 study. Visual Analog Scale (VAS) and Brief Pain Inventory (BPI) were completed at baseline and the end of study. Patients’ Global Impression of Change (PGIC) was completed at the end of study. Regression analyses examined relationships between VAS, BPI sleep interference by pain, and PGIC.

Result

At the end of treatment, 53.7 and 63.2 % of patients reported a ≥30 % reduction in VAS and BPI pain-associated sleep interference (BPISI) respectively; 46.3 % reported feeling “Much” or “Very Much” improved on the PGIC. There were positive correlations between the percent reductions in VAS and BPISI; both correlated with PGIC improvements. Percent changes in VAS and BPISI were significant (p < 0.0001 and p = 0.0082, respectively), and were independent predictors of feeling “Much” or “Very Much” improved on the PGIC.

Conclusion

Reductions in pain intensity and in BPISI were correlated, and both also correlated with overall impression of improvement for patients with PHN treated with G-GR. Both pain relief and improvement BPISI independently predicted improvement in PGIC. For optimal patient care, clinicians should consider reducing the impact of pain on quality of sleep as well as overall pain reduction.

Source:

Health Qual Life Outcomes

Article:

Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

Authors:

Neel Mehta et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: